RECRUITING

A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma

Talk to us

Conditions

Pancreatic CancerPancreatic DiseasesPancreatitisPancreatic Cyst17-257

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to develop a minimally invasive test to diagnose pancreatic cancer at early stages of disease and monitor response to treatment.

Official Title

Development of Biomarkers for the Early Detection, Surveillance and Monitoring of Pancreatic Ductal Adenocarcinoma

Quick Facts

Study Start:2017-10-30
Study Completion:2025-10-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT03334708

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Radiological, histological or cytological confirmed diagnosis of locally advanced or metastatic pancreatic adenocarcinoma by the enrolling institution
  2. * Patient planning to receive systemic treatment
  3. * Hemoglobin \> 8
  4. * ECOG performance status 0-2
  5. * A minimum age of 18 years old
  6. * Willing to undergo a tumor biopsy
  7. * Willing to provide permission to obtain banked tumor tissue for analysis (previous biopsies or surgical material).
  8. * Radiological, histological or cytological confirmed diagnosis of pancreatic adenocarcinoma by the enrolling institution
  9. * Patient planned to undergo upfront resection
  10. * No pre-operative systemic therapy nor chemoradiation therapy planned
  11. * Hemoglobin \> 8
  12. * ECOG performance status 0-2
  13. * A minimum age of 18 years old
  14. * Willing to undergo a tumor biopsy
  15. * Willing to provide permission to obtain banked tumor tissue for analysis (previous biopsies or surgical material).
  16. * Confirmed diagnosis of acute pancreatitis or other acute pancreatic pathology by the enrolling institution
  17. * Hemoglobin \> 8
  18. * ECOG performance status 0-2
  19. * A minimum age of 18 years old
  20. * Confirmed diagnosis of chronic pancreatitis or other non-cystic chronic pancreatic pathology by the enrolling institution
  21. * Hemoglobin \> 8
  22. * ECOG performance status 0-2
  23. * A minimum age of 18 years old
  24. * Confirmed diagnosis of IPMN without high risk features by the enrolling institution
  25. * A minimum age of 18 years old
  26. * Confirmed diagnosis of benign pancreatic cyst by the enrolling institution
  27. * A minimum age of 18 years old
  28. * A minimum age of 18 years old
  1. * Prior chemotherapy or radiation therapy for pancreatic cancer in the advanced setting
  2. * Prior chemotherapy or radiation therapy for pancreatic cancer within the last 6 months in the localized setting
  3. * Prior history of another malignancy, except non-melanoma skin cancer or low grade malignancy
  4. * Active second malignancy, unless low grade malignancy
  5. * Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures
  6. * Neoadjuvant chemotherapy or radiation therapy is planned
  7. * Prior history of another malignancy, except non-melanoma skin cancer or low grade malignancy
  8. * Active second malignancy, unless low grade malignancy
  9. * Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures
  10. * Active or prior malignancy, except prior non-melanoma skin cancer
  11. * Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer
  12. * Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures
  13. * Active or prior malignancy, except prior non-melanoma skin cancer
  14. * Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer
  15. * Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures
  16. * IPMN with high risk features or planned resection
  17. * Active or prior malignancy, except prior non-melanoma skin cancer
  18. * Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer
  19. * Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures
  20. * Active or prior malignancy, except prior non-melanoma skin cancer
  21. * Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer
  22. * Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures
  23. * Active or prior malignancy, except prior non-melanoma skin cancer
  24. * Proven to be a carrier of a cancer susceptibility gene or family history concerning for genetic predisposition to cancer
  25. * Any medical or psychiatric condition that may interfere with ability to comply with protocol procedures

Contacts and Locations

Study Contact

Kenneth Yu, MD
CONTACT
646-888-4188
yuk1@mskcc.org
David Kelson, MD
CONTACT
646-888-4179

Study Locations (Sites)

Memorial Sloan Kettering Monmouth (All protocol activities)
Middletown, New Jersey, 07748
United States
Memorial Sloan Kettering Bergen (All protocol activities)
Montvale, New Jersey, 07645
United States
Cold Springs Harbor Laboratory (Specimen Analysis)
Cold Spring Harbor, New York, 11724
United States
Memorial Sloan Kettering Cancer Center @ Commack (All Protocol Activities)
Commack, New York, 11725
United States
Memorial Sloan Kettering Westchester (All protocol activities)
Harrison, New York, 10604
United States
New York University
New York, New York, 10010
United States
Memorial Sloan - Kettering Cancer Center
New York, New York, 10021
United States
Memorial Sloan Kettering Basking Ridge (All protocol activities)
New York, New York, 10065
United States
Weill Cornell Medical Center
New York, New York, 10065
United States
Memorial Sloan Kettering Nassau (All protocol activities)
Rockville Centre, New York, 11553
United States

Collaborators and Investigators

Sponsor: Memorial Sloan Kettering Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2017-10-30
Study Completion Date2025-10-30

Study Record Updates

Study Start Date2017-10-30
Study Completion Date2025-10-30

Terms related to this study

Keywords Provided by Researchers

  • 17-257

Additional Relevant MeSH Terms

  • Pancreatic Cancer
  • Pancreatic Diseases
  • Pancreatitis
  • Pancreatic Cyst